Imprinted antibody responses against SARS-CoV-2 Omicron sublineages-Reference-Cited by-同舟云学术

Imprinted antibody responses against SARS-CoV-2 Omicron sublineages

Published:2022-11-11 Issue:6620 Volume:378 Page:619-627
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Park Young-Jun¹²^ORCID,Pinto Dora³,Walls Alexandra C.¹²^ORCID,Liu Zhuoming⁴^ORCID,De Marco Anna³^ORCID,Benigni Fabio³^ORCID,Zatta Fabrizia³^ORCID,Silacci-Fregni Chiara³,Bassi Jessica³^ORCID,Sprouse Kaitlin R.¹^ORCID,Addetia Amin¹^ORCID,Bowen John E.¹^ORCID,Stewart Cameron¹^ORCID,Giurdanella Martina³,Saliba Christian³^ORCID,Guarino Barbara³^ORCID,Schmid Michael A.³^ORCID,Franko Nicholas M.⁵^ORCID,Logue Jennifer K.⁵^ORCID,Dang Ha V.⁶^ORCID,Hauser Kevin⁶,di Iulio Julia⁶^ORCID,Rivera William⁶,Schnell Gretja⁶,Rajesh Anushka⁶,Zhou Jiayi⁶^ORCID,Farhat Nisar⁶^ORCID,Kaiser Hannah⁶^ORCID,Montiel-Ruiz Martin⁶^ORCID,Noack Julia⁶^ORCID,Lempp Florian A.⁶^ORCID,Janer Javier⁴^ORCID,Abdelnabi Rana⁷^ORCID,Maes Piet⁷^ORCID,Ferrari Paolo⁸⁹¹⁰^ORCID,Ceschi Alessandro⁸¹¹¹²¹³^ORCID,Giannini Olivier⁸¹⁴^ORCID,de Melo Guilherme Dias¹⁵^ORCID,Kergoat Lauriane¹⁵^ORCID,Bourhy Hervé¹⁵^ORCID,Neyts Johan⁷^ORCID,Soriaga Leah⁶^ORCID,Purcell Lisa A.⁶^ORCID,Snell Gyorgy⁶^ORCID,Whelan Sean P. J.⁴^ORCID,Lanzavecchia Antonio³^ORCID,Virgin Herbert W.⁶¹⁶¹⁷^ORCID,Piccoli Luca³^ORCID,Chu Helen Y.⁵^ORCID,Pizzuto Matteo Samuele³^ORCID,Corti Davide³^ORCID,Veesler David¹²^ORCID

Affiliation:

1. Department of Biochemistry, University of Washington, Seattle, WA, USA.

2. Howard Hughes Medical Institute, University of Washington, Seattle, WA, USA.

3. Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.

4. Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, USA.

5. Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA, USA.

6. Vir Biotechnology, San Francisco, CA, USA.

7. KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, B-3000 Leuven, Belgium.

8. Faculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland.

9. Division of Nephrology, Ente Ospedaliero Cantonale, Lugano, Switzerland.

10. Clinical School, University of New South Wales, Sydney, New South Wales, Australia.

11. Clinical Trial Unit, Ente Ospedaliero Cantonale, Lugano, Switzerland.

12. Division of Clinical Pharmacology and Toxicology, Institute of Pharmacological Sciences of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland.

13. Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, Zurich, Switzerland.

14. Department of Medicine, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.

15. Institut Pasteur, Université Paris Cité, Lyssavirus Epidemiology and Neuropathology Unit, F-75015 Paris, France.

16. Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.

17. Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA.

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron sublineages carry distinct spike mutations resulting in escape from antibodies induced by previous infection or vaccination. We show that hybrid immunity or vaccine boosters elicit plasma-neutralizing antibodies against Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5, and that breakthrough infections, but not vaccination alone, induce neutralizing antibodies in the nasal mucosa. Consistent with immunological imprinting, most antibodies derived from memory B cells or plasma cells of Omicron breakthrough cases cross-react with the Wuhan-Hu-1, BA.1, BA.2, and BA.4/5 receptor-binding domains, whereas Omicron primary infections elicit B cells of narrow specificity up to 6 months after infection. Although most clinical antibodies have reduced neutralization of Omicron, we identified an ultrapotent pan-variant–neutralizing antibody that is a strong candidate for clinical development.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference126 articles.

1. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa

2. J. Yu A.-R. Y. Collier M. Rowe F. Mardas J. D. Ventura H. Wan J. Miller O. Powers B. Chung M. Siamatu N. P. Hachmann N. Surve F. Nampanya A. Chandrashekar D. H. Barouch Comparable neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 variants. medRxiv 2022.02.06.22270533 [Preprint] (2022); https://doi.org/10.1101/2022.02.06.22270533.10.1101/2022.02.06.22270533

3. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift

4. Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines

5. Comparative neutralisation profile of SARS-CoV-2 omicron subvariants BA.2.75 and BA.5

Cited by 143 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Finite immune imprinting on neutralizing antibody responses to Omicron subvariants by repeated vaccinations;International Journal of Infectious Diseases;2024-10

2. Beyond COVID-19: the promise of next-generation coronavirus vaccines;npj Viruses;2024-08-22

3. XBB.1.16‐RBD‐based trimeric protein vaccine can effectively inhibit XBB.1.16‐included XBB subvariant infection;MedComm;2024-08-16

4. Profiling serum immunodominance following SARS-CoV-2 primary and breakthrough infection reveals distinct variant-specific epitope usage and immune imprinting;2024-08-15

5. Variant-proof high affinity ACE2 antagonist limits SARS-CoV-2 replication in upper and lower airways;Nature Communications;2024-08-12